ArticleCrohn's & colitis 3602026
Anti-OmpC antibodies in Crohn's disease and ulcerative colitis: evidence from a systematic review and meta-analysis.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Anti-OmpC antibodies target the Methods: We performed a systematic review and meta-analysis (PROSPERO CRD420251066959) of 31 studies including ∼11 000 participants with CD, UC, and controls. Random-effects models estimated pooled prevalence, odds ratios (OR), sensitivity, specificity, diagnostic odds ratios (DOR), and summary receiver operating characteristic curves. Subgroup and sensitivity analyses were performed by assay cutoff, and publication bias was evaluated with funnel plots, Egger's regression, and trim-and-fill. Results: For CD, 11 studies compared patients with controls; 8 using standardized ELISA cutoffs showed a strong association (OR = 6.99, 95% CI 3.99-12.23; I Conclusions: Anti-OmpC antibodies are strongly associated with CD and show a supportive but less consistent association in UC, with high specificity but limited sensitivity. In CD, OmpC positivity is associated with complicated disease behavior and increased odds of surgery, although these findings should be interpreted cautiously given the observational nature of the included studies. Incorporation into multi-marker serological panels may enhance diagnostic confidence and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.